Table 3 WSP test for immune thrombocytopenia associated with ICIs.
From: Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors
Drug | Cases (n) | TTO (days) | Scale parameter α (95% CI) | Shape parameter β (95% CI) | Failure type | |
|---|---|---|---|---|---|---|
Median (IQR) | Min–max | |||||
PD-1 | 112 | 47(21-139.2) | 1-860 | 91.40 (69.398–113.41) | 0.81 (0.70–0.93) | Early failure |
Nivolumab | 70 | 50.5(14.75-146.75) | 1-860 | 94.94 (64.45-125.43) | 0.77 (0.63–0.91) | Early failure |
Pembrolizumab | 41 | 42(22–90) | 1-598 | 86.03 (54.98-117.09) | 0.90 (0.70–1.10) | Random failure |
Cemiplimab | 1 | |||||
PD-L1 | 33 | 21(13–131) | 1-439 | 74.43 (37.39-111.47) | 0.73 (0.54–0.92) | Early failure |
Atezolizumab | 20 | 21(11-120.5) | 1-439 | 66.26 (20.72-111.81) | 0.68 (0.45–0.90) | Early failure |
Durvalumab | 10 | 28(15-95.25) | 1-439 | 74.28 (10.88-137.67) | 0.77 (0.42–1.12) | Random failure |
Avelumab | 3 | |||||
CTLA-4 | 13 | 9(7–27) | 2–62 | 21.03 (10.00-32.07) | 1.09 (0.63–1.56) | Random failure |
Ipilimumab | 13 | 9(7–27) | 2–62 | 21.03 (10.00-32.07) | 1.09 (0.63–1.56) | Random failure |
Tremelimumab | 0 | 0 | 0 | 0 | 0 | |
